Phaseline

Companies › HighField Biopharmaceuticals

HighField Biopharmaceuticals: clinical trials, targets and expected readouts

3 active drug programs in 21 registered trials: 13 Phase 2, 3 Phase 3, 3 Phase 1, 2 Phase 4; Oncology, Gastroenterology, Immunology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tretinoin
Retinoic acid receptor agonist
RARG, RARB, RARAPhase 2Glioma; Acne Vulgaris; Melasma (Facial Melasma); APL …Dec 2028
HF158K1
Liposomal doxorubicin with HER2-directed trastuzumab Fab fragment
ERBB2Phase 1Solid Tumors, AdultJun 2027
HF50
Liposome-encapsulated bifunctional therapeutic; HER2-redirected T-cell engager with TLR7/8
ERBB2, TLR7, TLR8Phase 1Advanced Solid TumorsJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06158412TretinoinPhase 2Multiple Myeloma in RelapseOncologyDec 2025
NCT06439888TretinoinPhase 1Oligometastatic DiseaseOncologyJan 2027
NCT07915648TretinoinPhase 4Acne VulgarisImmunologyMar 2027
NCT05345002TretinoinPhase 2GliomaOncologyJun 2027
NCT05861895HF158K1Phase 1Solid Tumors, AdultOncologyJun 2027
NCT06358677TretinoinPhase 2Metastatic Solid TumorOncologyJul 2027
NCT04793919TretinoinPhase 2Acute Promyelocytic LeukemiaOncologyOct 2027
NCT07893067TretinoinPhase 4Melasma (Facial Melasma)ImmunologyOct 2027
NCT06731140TretinoinPhase 2HER2 Negative Breast CancerOncologyOct 2027
NCT07586813TretinoinPhase 2Persistent Isolated Chemotherapy-Induced ThrombocytopeniaGastroenterologyOct 2027
NCT07586826TretinoinPhase 2Persistent Isolated Chemotherapy-Induced ThrombocytopeniaOncologyOct 2027
NCT06484920TretinoinPhase 2Relapsed Hodgkin LymphomaOncologyDec 2027
NCT01409161TretinoinPhase 2Acute Promyelocytic Leukemia With PML-RARAOncologyDec 2027
NCT06528769TretinoinPhase 2LeiomyosarcomaOncologyDec 2027
NCT07503730TretinoinPhase 3APLOncologyJun 2028
NCT04241276TretinoinPhase 2Pancreatic CancerOncologyJun 2028
NCT07601334HF50Phase 1Advanced Solid TumorsOncologyJun 2028
NCT05999812TretinoinPhase 2Colorectal CancerOncologyOct 2028
NCT07678684TretinoinPhase 2GliomaOncologyDec 2028
NCT06706401TretinoinPhase 3Oropharynx CancerOncologyJan 2029
NCT02339740TretinoinPhase 3Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARAOncologyJun 2029

Targets

ERBB2 (2) RARG (1) RARB (1) RARA (1) TLR7 (1) TLR8 (1)

Companies with the same targets

Beijing Biotech Roche Merck KGaA Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical IR INNOVATE RESEARCH PRIVATE Suzhou Suncadia Biopharmaceuticals Pfizer Sichuan Baili Pharmaceutical Shanghai Henlius Biotech

Companies built like this

Nuvalent SystImmune Nanjing Leads Biolabs Institut de Recherches Internationales Servier (I.R.I.S.) Zhejiang Hisun Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.